Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)

Severe Clostridium Difficile Infection Clinical Trial

Official title: A Phase II, Randomized Trial to Evaluate the Safety and Efficacy of Fecal Microbiota Transplantation Using the Penn Microbiome Therapy Products for Severe or Severe-Complicated/Fulminant Clostridium Difficile Infection

Status Terminated

Clinical Trial Summary

This is a randomized, open label, comparative, Phase II study to determine whether fecal microbiota transplant using Penn Microbiome Therapy products helps standard therapy to treat severe Clostridium difficile infection (C diff).

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Clostridium Infections
• Communicable Diseases
• Infections
• Severe Clostridium Difficile Infection
• Severe-Complicated/Fulminant Clostridium Difficile Infection

• NCT number: NCT03970200
• Study type: Interventional
• Source: University of Pennsylvania
• Status: Terminated
• Phase: Phase 2
• Start date: January 16, 2020
• Completion date: May 14, 2022